VentriPoint Diagnostics (CVE:VPT) Hits New 1-Year Low – Should You Sell?

Shares of VentriPoint Diagnostics Ltd. (CVE:VPT) reached a new 52-week low on Thursday. The stock traded as low as C$0.08 and last traded at C$0.08, with a volume of 63,000 shares. The stock had previously closed at C$0.09.

VentriPoint Diagnostics Stock Performance

The stock has a market capitalization of C$16.39 million, a P/E ratio of -4.25 and a beta of -1.07. The company has a quick ratio of 6.67, a current ratio of 0.12 and a debt-to-equity ratio of -68.25. The business has a fifty day moving average price of C$0.09 and a 200-day moving average price of C$0.11.

VentriPoint Diagnostics Company Profile

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients.